NCT03227796View on ClinicalTrials.gov

Safety, Tolerability & Pharmacokinetics of LEVI-04 in Healthy Volunteers and Patients With Osteoarthritis Knee Pain

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

July 28, 2017

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
Healthy VolunteersOsteoarthritis
Interventions
DRUG

LEVI-04

LEVI-04 intravenous infusion

DRUG

Placebo

Placebo intravenous infusion

Trial Locations (2)

M13 9NQ

MAC Clinical Research - Early Phase Unit, Manchester

NW10 7EW

Hammersmith Medicines Research, London

Sponsors

Lead Sponsor

Levicept

Collaborators (1)

MAC Clinical Research
All Listed Sponsors
collaborator

Hammersmith Medicines Research

OTHER

collaborator

MAC Clinical Research

OTHER

lead

Levicept

INDUSTRY

NCT03227796 - Safety, Tolerability & Pharmacokinetics of LEVI-04 in Healthy Volunteers and Patients With Osteoarthritis Knee Pain | Biotech Hunter | Biotech Hunter